3
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Linfoma no Hodgkin primario de esófago: Reporte de un caso

      case-report

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          El Linfoma esofágico primario es un tumor muy raro, representa menos del 1% de los tumores esofágicos. Se reporta el caso un paciente con linfoma no Hodgkin localizado en esófago medio e inferior, que consulta por disfagia, siendo diagnosticado y tratado exitosamente con quimioterapia, con sobrevida de 12 meses, hasta la actualidad asintomático y sin evidencia de tumor.

          Translated abstract

          SUMMARY Primary esophageal lymphoma is a very rare tumor; represents less than 1 % of all esophageal tumors. We report a case of a patient with no-Hodgkin lymphoma involving the medial and lower esophagus, presenting with dysphagia, he was treated successfully with chemotherapy, with an over all survival of 12 months. He is at the moment, asymptomatic and without evidence of tumor.

          Related collections

          Most cited references24

          • Record: found
          • Abstract: found
          • Article: not found

          Gastrointestinal involvement in non-Hodgkin's lymphoma.

          A total of 813 patients admitted to Roswell Park Memorial Institute from 1963--1972 with non Hodgkin's lymphoma (NHL) were reviewed for gastrointestinal (GI) involvement. Primary involvement was found in 71 and secondary involvement in 31 patients. Occult GI involvement was detected in 46% of the autopsy cases. The median survival time after the diagnosis of secondary GI involvement was nine months. The occurrence of primary GI-NHL was: 33 in the stomach, 18 in the small intestine, 14 in the ileocecal area including appendix, and 6 in the large intestine. Retrospective staging according to the Ann Arbor staging classification showed 24 to have presented as Stage I, 30 as Stage II, 4 as Stage III, and 13 as Stage IV. The primary diagnostic and therapeutic approach was operative, except in 2 patients with rectal lymphoma. Resection of the principally involved site was carried out in 42 patients. The remainder had palliative procedures or biopsy examinations only. Postoperative radiation therapy was given to 38 patients. Prognostically important features for primary GI-NHL were: stage; histologic type; site of the primary disease; and whether or not radiotherapy was administered. The age of the patient, size or degree of local extension, and type of operative procedure were prognostically of no importance. The results of this study would indicate that in Stage I and II primary GI-NHL, elective resection is not necessary prior to radiation therapy and that resection alone cannot be considered adequate treatment. A modified staging classification is proposed.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Lymphosarcoma: a review of 1269 cases.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              AIDS-associated non-Hodgkin's lymphoma in San Francisco.

              The characteristics of acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma in 84 patients diagnosed and treated at San Francisco General Hospital are presented herein. While the majority were high-grade B-cell lymphomas, one cutaneous T-cell and one peripheral T-cell lymphoma were observed. In addition, three other tumors were suspicious for T-cell lymphoma. Sixty-seven percent of patients had stage IV disease, often at unusual sites. Epstein-Barr virus DNA sequences were identified in only five of 15 tumors by dot-blot analysis. Patients were treated with a variety of standard chemotherapeutic regimens, with radiation therapy alone, or with a novel chemotherapy protocol (COMET-A). No significant differences in complete response rates were observed. The most important predictor of survival was the total number of CD4-positive lymphocytes. Other predictors of survival included history of a diagnosis of acquired immunodeficiency syndrome, Karnofsky performance score, and the presence of extranodal disease. Survival was shorter among patients who received higher doses of cyclophosphamide (greater than 1 g/m2), including those treated with the COMET-A regimen. Implications for therapeutic decision making are discussed.
                Bookmark

                Author and article information

                Contributors
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Journal
                gen
                Gen
                Gen
                Sociedad Venezolana de Gastroentereología (Caracas )
                0016-3503
                December 2006
                : 60
                : 4
                : 317-319
                Affiliations
                [1 ] Centro de Control de Cáncer Gastrointestinal Dr. Luis E. Anderson
                Article
                S0016-35032006000400015
                6f685980-2dd5-43af-8958-b0f237c691fa

                http://creativecommons.org/licenses/by/4.0/

                History
                Product

                SciELO Venezuela

                Self URI (journal page): http://www.scielo.org.ve/scielo.php?script=sci_serial&pid=0016-3503&lng=en

                primary esophageal lymphoma,no- Hodgkin lymphoma,Linfoma esofágico primario,linfoma no Hodgkin

                Comments

                Comment on this article